FDA Commissioner Marty Makary Resigns Amid Controversy and Policy Disputes
Washington, D.C. — Dr. Marty Makary, the prominent Johns Hopkins surgeon and FDA Commissioner, has announced his resignation from the Food and Drug Administration, marking another high-profile shakeup in President Donald Trump’s second-term administration. His departure comes amid mounting pressures over controversial health policies, internal agency disputes, and policy clashes that have defined his tenure.
Makary is expected to step down Tuesday, ending a turbulent chapter at one of the nation’s most influential public health agencies.
Makary’s Background: From Johns Hopkins to the FDA
Dr. Marty Makary rose to national prominence as a surgical oncologist and public health commentator. Before his appointment to the FDA, Makary earned recognition during the COVID-19 pandemic for his critiques of vaccine mandates, lockdown measures, and government health policy.
In March 2025, he was confirmed by the Senate to lead the FDA after being nominated by President Trump. His confirmation was seen as a signal of the administration’s commitment to reform federal health agencies, with a focus on accelerating approvals for pharmaceuticals, medical devices, and novel health interventions.
Controversies During Makary’s Tenure
Makary’s time at the FDA has been defined by policy disputes and internal agency tensions. Several key issues contributed to the pressure surrounding his resignation:
Vaping Policy and Flavored E-Cigarettes
Makary faced criticism from vaping advocates, public health groups, and some Trump allies over delays in approving flavored e-cigarettes. Supporters argued the FDA under Makary had slowed access to alternatives for adult smokers, while opponents claimed he moved too quickly in relaxing regulations that could expose youth to nicotine.
Abortion Drug Reviews
The FDA Commissioner also faced scrutiny from anti-abortion groups frustrated with the pace of regulatory decisions regarding mifepristone, the abortion pill. His cautious approach drew criticism from conservative activists who felt the FDA should have restricted access more aggressively, adding friction with key political allies.
Internal Agency Turmoil
Staffing upheavals and internal conflicts further complicated Makary’s leadership. Reports of high turnover among senior staff, combined with friction between career civil servants and political appointees, contributed to a sense of instability within the FDA. Some employees reportedly expressed concern about policy decisions being influenced by politics rather than science.
Praise From Conservatives
Despite controversy, Makary earned accolades from conservative commentators and public health reform advocates. His supporters praised him for challenging entrenched public health orthodoxy, advocating for faster drug approvals, and collaborating with HHS Secretary Robert F. Kennedy Jr. to push reforms across federal health agencies.
His tenure highlighted a broader trend within the Trump administration to prioritize efficiency and deregulation in federal health operations, a stance that resonated with business leaders and pro-reform policymakers.
The White House’s Role
President Trump had reportedly pre-approved plans to replace Makary even before his resignation was announced publicly. The timing reflects broader efforts by the administration to stabilize leadership in health agencies ahead of the 2026 midterm elections, ensuring that public health operations remain politically aligned and functional.
Who Will Replace Makary?
While no permanent successor has been announced, FDA Deputy Commissioner for Food Kyle Diamantas is expected to step into the role in an acting capacity. Diamantas, a veteran career civil servant, is anticipated to maintain continuity during the transition, focusing on ongoing reviews of pharmaceuticals, medical devices, and public health guidance.
Observers note that the selection of a permanent replacement could signal policy priorities for the administration in the final months before the midterms, particularly regarding vaping regulations, reproductive health drugs, and pandemic preparedness initiatives.
Broader Implications for Federal Health Leadership
Makary’s resignation adds to a growing list of leadership changes across Trump’s health agencies, including the Centers for Disease Control and Prevention and the National Institutes of Health. Analysts suggest that frequent turnover in top health positions could impact agency morale, regulatory consistency, and public trust, especially amid high-stakes debates over reproductive health and public safety.
Some critics argue that these shifts risk politicizing health policy, while proponents contend that fresh leadership can streamline bureaucracy and advance reforms more effectively.
Public and Industry Reactions
The healthcare community has responded with mixed reactions.
- Pharmaceutical executives expressed cautious optimism, noting that Makary’s focus on reducing regulatory bottlenecks had been beneficial for drug development timelines.
- Public health advocates voiced concerns that policy reversals or leadership changes could stall critical initiatives, particularly those aimed at youth nicotine prevention and safe reproductive care.
- Conservative commentators praised Makary for challenging “government overreach” and for implementing pragmatic reforms.
Makary’s Legacy
Despite a controversial tenure, Dr. Makary’s legacy is likely to be remembered for:
- Pushing for accelerated drug and device approvals to promote innovation.
- Advocating for public health reforms alongside HHS leadership.
- Navigating complex political pressures, balancing administration priorities with scientific and ethical considerations.
Looking Forward
As the FDA transitions leadership, policy continuity will be a central concern. Ongoing debates over vaping, abortion medications, and pharmaceutical innovation will likely shape public perception of federal health agencies and could influence the administration’s standing ahead of the 2026 elections.
The Trump administration faces the challenge of maintaining stability in federal health governance while advancing its reform agenda, especially with public scrutiny on key health issues at an all-time high.
Conclusion
Dr. Marty Makary’s resignation represents a significant moment for the FDA and the broader U.S. health policy landscape. His departure underscores the delicate balance between political leadership and scientific integrity in federal health agencies.
As the administration moves forward, the appointment of a permanent successor and the handling of ongoing public health issues will be closely watched by industry, policymakers, and the American public alike.